These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 8998181

  • 1. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 2. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.
    Blood; 1996 Aug 01; 88(3):1005-12. PubMed ID: 8704208
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 01; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B.
    J Exp Med; 1995 Dec 01; 182(6):1645-53. PubMed ID: 7500009
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM.
    Leuk Lymphoma; 1993 Dec 01; 11 Suppl 1():131-7. PubMed ID: 7504543
    [Abstract] [Full Text] [Related]

  • 11. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P.
    Leuk Lymphoma; 1999 Nov 01; 35(5-6):471-81. PubMed ID: 10609784
    [Abstract] [Full Text] [Related]

  • 12. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ.
    Leukemia; 1995 Jan 01; 9(1):118-30. PubMed ID: 7845006
    [Abstract] [Full Text] [Related]

  • 13. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 01; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 14. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R.
    Oncogene; 2005 May 05; 24(20):3246-56. PubMed ID: 15735695
    [Abstract] [Full Text] [Related]

  • 15. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 05; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 16. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
    Nieborowska-Skórska M, Białek AP, Nicolaides NC, Iozzo RV, Kawalec M, Calabretta B, Kawiak J, Marlicz K, Skórski T.
    Folia Histochem Cytobiol; 1996 Jan 05; 34(2):69-73. PubMed ID: 8875213
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
    Nieborowska-Skórska M, Nakashima M, Ratajczak M, Steplewski Z, Calabretta B, Skórski T.
    Folia Histochem Cytobiol; 1994 Jan 05; 32(1):35-40. PubMed ID: 8026602
    [Abstract] [Full Text] [Related]

  • 20. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
    Nieborowska-Skórska M, Skórski T, Ratajczak MZ, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1993 Jan 05; 31(4):161-7. PubMed ID: 8137996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.